1. Pageaux GP, Rostaing L, Calmus Y, Duvoux C, Vanlemmens C. Hardgwissen J, et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2006;12:1755-1760. 17133564.
2. Arns W, Cibrik DM, Walker RG, Mourad G, Budde K, Mueller EA, et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation 2006;82:1004-1012. 17060847.
3. Hwang S, Lee SG, Ahn CS, Kim KH, Moon DB, Ha TY, et al. A clinical assessment of mycophenolate drug monitoring after liver transplantation. Clin Transplant 2010;24:E35-E42. 20070319.
4. Kaplan B. Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome. Curr Med Res Opin 2006;22:2355-2364. 17257450.
5. Premaud A, Le Meur Y, Debord J, Szelag JC, Rousseau A, Hoizey G, et al. Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit 2005;27:354-361. 15905807.
6. Tredger JM, Brown NW, Adams J, Gonde CE, Dhawan A, Rela M, et al. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl 2004;10:492-502. 15048791.
7. Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M, et al. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev (Orlando) 2011;25:47-57. 21190834.
9. Suhail SM, Vathsala A, Lou HX, Woo KT. Safety and efficacy of mycophenolate mofetil for prophylaxis in Asian renal transplant recipients. Transplant Proc 2000;32:1757-1758. 11119922.
10. Naito T. [Optimal immunosuppressive therapy based on pharmacokinetics and pharmacodynamics of antimetabolites in clinical practice]. Yakugaku Zasshi 2010;130:1695-1700. 21139397.
11. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009;250:187-196. 19638912.
12. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-663. 9049215.
13. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996;61:1029-1037. 8623181.
14. van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006;28:145-154. 16628123.
15. Shaw LM, Figurski M, Milone MC, Trofe J, Bloom RD. Therapeutic drug monitoring of mycophenolic acid. Clin J Am Soc Nephrol 2007;2:1062-1072. 17702714.
16. Lampon N, Tutor-Crespo MJ, Romero R, Tutor JC. Diagnostic efficiency of truncated area under the curve from 0 to 2 h (AUC
0-2) of mycophenolic acid in kidney transplant recipients receiving mycophenolate mofetil and concomitant tacrolimus. Clin Chem Lab Med 2011;49:1167-1170. 21574884.
17. van Gelder T. Mycophenolate blood level monitoring: recent progress. Am J Transplant 2009;9:1495-1499. 19519824.
18. Bruchet NK, Ensom MH. Limited sampling strategies for mycophenolic acid in solid organ transplantation: a systematic review. Expert Opin Drug Metab Toxicol 2009;5:1079-1097. 19689217.
19. Le Meur Y1, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007;7:2496-2503. 17908276.
20. Barraclough KA, Isbel NM, Franklin ME, Lee KJ, Taylor PJ, Campbell SB, et al. Evaluation of limited sampling strategies for mycophenolic acid after mycophenolate mofetil intake in adult kidney transplant recipients. Ther Drug Monit 2010;32:723-733. 21068647.
21. Brunet M, Cirera I, Martorell J, Vidal E, Millan O, Jimenez O, et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation 2006;81:541-546. 16495801.
22. Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003;14:2381-2386. 12937317.
23. Mourad M, Malaise J, Chaib Eddour D, De Meyer M, König J, Schepers R, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001;47:88-94. 11148182.
24. Pelletier RP, Akin B, Henry ML, Bumgardner GL, Elkhammas EA, Rajab A, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003;17:200-205. 12780668.
25. Dumortier J, Guillaud O, Pittau G, Salandre J, Adham M, Scoazec JY, et al. Introduction of mycophenolate mofetil in maintenance liver transplant recipients: what can we expect? Results of a 10-year experience. Transplant Proc 2010;42:2602-2606. 20832553.
26. Pfitzmann R, Klupp J, Langrehr JM, Uhl M, Neuhaus R, Settmacher U, et al. Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation 2003;76:130-136. 12865798.
27. Sollinger HW. Mycophenolates in transplantation. Clin Transplant 2004;18:485-492. 15344948.
28. Hardinger KL, Brennan DC, Lowell J, Schnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 2004;17:609-616. 15517170.
29. Banff Working Group. Demetris AJ, Adeyi O, Bellamy CO, Clouston A, Czaja A, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006;44:489-501. 16871565.
30. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-207. 12547409.
31. Crespo G1, Mariño Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012;142:1373-1383. 22537446.
32. Burra P, Germani G, Adam R, Karam V, Marzano A, Lampertico P, et al. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol 2013;58:287-296. 23099188.
33. Yi NJ, Suh KS, Suh SW, Chang YR, Hong G, Yoo T, et al. Excellent outcome in 238 consecutive living donor liver transplantations using the right liver graft in a large volume single center. World J Surg 2013;37:1419-1429. 23467924.